DR REDDY - DIRT CHEAP - LONG LONG LONG Recently, DRL was in the news for receiving a “Notice of Non-Compliance” from the Canadian regulator concerning its filing for the generic version of Semaglutide (used for type-2 diabetes/obesity).
However, when one steps back and looks at the broader business picture, the fear looks over-blown:
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.696 EUR
618.19 M EUR
3.56 B EUR
832.36 M
About Dr. Reddy's Laboratories Ltd.
Sector
Industry
CEO
Erez Israeli
Website
Headquarters
Hyderabad
Founded
1984
ISIN
US2561352038
FIGI
BBG000NX6460
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Related stocks
Dr Reddy ,option buying(1260Ce)
Monthly price has crossed 20ema, currently price has entered one weekly tested supply zone.
Weekly all the supply zones are tested ,and currently price is moving from a point where previous upward rally was observed.
In daily time zone , one gap which was created by previous downfall i
DRREDDY BREAKOUT CHART PATTERNPOTENTIAL INVERSE HEAD AND SHOULDERS PATTERN IN MAKING
{ WEEKLY TIMEFRAME } - GOOD CHANCES OF BREAKOUT
STRONG RESULTS AND EARNING SEASON AHEAD.
HOW TO TAKE POSITIONS IN THIS -
ENTRY LEVELS - 1 DAY CANDLE CLOSIGN ABOVE 1350
STOP LOSS LEVELS - AROUND 1150
TARGET 1 - 1500
TARGET 2 - 1650
TARGET
DRREDDY–Weekly Chart AnalysisThe stock is currently trading near ₹1,322 and is once again testing the long-term descending trendline resistance that has capped every rally since 2023. This resistance lies in the ₹1,345–₹1,348 zone and represents the key decision point for the next move.
Bullish Scenario (if breakout holds)
DRREDDY Bullish ProjectionMETHODOLOGY SUMMARY
Mathematical Transformation: Uses square root, cube root, and 4th root of price to identify natural support/resistance levels
Perfect Level Calculation: Round roots to nearest integer, then power back to create "perfect" mathematical anchors
Multi-Timeframe Analysis:
Sq
Dr. Reddy's (Weekly Timeframe) - Potential BreakOut?Dr. Reddy's Laboratories is currently in a phase of strategic consolidation. After a remarkable 93.63% uptrend that began in March 2022, the stock has settled into a well-defined triangle formation since August 2024. This pattern suggests a temporary equilibrium between buyers and sellers as the mar
NSE:DRREDDY - Medium Term Swing Trade Opprotunity💹 Weekly Charts::
Price is consolidating around ₹1,300 after a bounce from the ₹1,150–1,180 zone (strong support zone).
Major resistance levels:
₹1,350–1,360 (R1 zone & trendline resistance)
₹1,415 (swing high and R2 zone)
Weekly RSI ~60, showing improving momentum but not yet overbought.
MACD
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.









